Back |
home / stock / ptn / ptn message board
Subject | By | Source | When |
---|---|---|---|
I will take 50,60 or 70 company will | zeusgodmd | investorshub | 12/23/2022 10:00:15 PM |
Does not look like a stock going off | zeusgodmd | investorshub | 12/22/2022 8:10:02 PM |
Doubled my bet today | zeusgodmd | investorshub | 12/22/2022 4:42:47 PM |
No company will be bought before eye drops | zeusgodmd | investorshub | 12/22/2022 4:42:20 PM |
I don't know but $PTN stock price is | mike1986 | investorshub | 12/08/2022 5:13:05 PM |
Do analyst stated price targets have any real | BesaoT35 | investorshub | 11/22/2022 7:14:04 PM |
Given 70 price up grade and going down | zeusgodmd | investorshub | 11/16/2022 10:53:37 PM |
Every time this company says boo there is | mike1986 | investorshub | 11/14/2022 7:28:36 PM |
Correction: The disease addressed in the presentation | BesaoT35 | investorshub | 10/28/2022 4:41:43 PM |
$PTN is up 20% in the past few | BesaoT35 | investorshub | 10/26/2022 6:25:04 PM |
I hadnt considered management getting paid to stifle | BesaoT35 | investorshub | 09/27/2022 2:39:54 PM |
You are exactly right. Men should not be | Monroe1 | investorshub | 09/22/2022 9:12:51 PM |
News, Short Squeeze, Breakout and More Instantly...
Palatin Technologies Inc. Company Name:
PTN Stock Symbol:
NYSE Market:
Palatin Technologies Inc. Website:
Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds PR Newswire CRANBURY, N.J. , June 21, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing fi...
Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED) PR Newswire In ED patients that do not respond to PDE5i monotherapy ~30-40% of ED patients do not respond to PDE5...
Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity PR Newswire Co-Administration Phase 2 study of bremelanotide with tirzepatide (GLP-1) to provide key information for melanocortin treatments of obesity Topline data expected by end...